Skip to main content
SpringerLink
Log in

Lack of PCSK9i use impacts cardiovascular outcomes

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. prior authorisation

References

  1. Myers KD, et al. Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular Outcomes. Circulation: Cardiovascular Quality and Outcomes 12: No. 8, 23 Jul 2019. Available from: URL: https://doi.org/10.1161/CIRCOUTCOMES.118.005404

  2. Nasir K, et al. PCSK9 Inhibitors Prior Authorization. Redundant Process Due for a Redesign. Circulation: Cardiovascular Quality and Outcomes 12: No. 8, 23 Jul 2019. Available from: URL: https://doi.org/10.1161/CIRCOUTCOMES.119.005910

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lack of PCSK9i use impacts cardiovascular outcomes. PharmacoEcon Outcomes News 834, 23 (2019). https://doi.org/10.1007/s40274-019-6123-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-6123-z

Search

Navigation